Charles Schwab’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.67M | Buy |
387,782
+6,423
| +2% | +$44.2K | ﹤0.01% | 2585 |
|
|
2025
Q1 | $1.1M | Sell |
381,359
-144,686
| -28% | -$417K | ﹤0.01% | 2806 |
|
|
2024
Q4 | $2.47M | Sell |
526,045
-43,140
| -8% | -$203K | ﹤0.01% | 2612 |
|
|
2024
Q3 | $2.03M | Buy |
569,185
+393,202
| +223% | +$1.4M | ﹤0.01% | 2702 |
|
|
2024
Q2 | $1.09M | Buy |
175,983
+151,498
| +619% | +$939K | ﹤0.01% | 2905 |
|
|
2024
Q1 | $231K | Hold |
24,485
| – | – | ﹤0.01% | 3217 |
|
|
2023
Q4 | $165K | Hold |
24,485
| – | – | ﹤0.01% | 3298 |
|
|
2023
Q3 | $109K | Hold |
24,485
| – | – | ﹤0.01% | 3344 |
|
|
2023
Q2 | $80.8K | Sell |
24,485
-116,826
| -83% | -$386K | ﹤0.01% | 3363 |
|
|
2023
Q1 | $403K | Buy |
141,311
+26,424
| +23% | +$75.3K | ﹤0.01% | 3020 |
|
|
2022
Q4 | $836K | Buy |
114,887
+22,116
| +24% | +$161K | ﹤0.01% | 2831 |
|
|
2022
Q3 | $751K | Buy |
92,771
+6,852
| +8% | +$55.5K | ﹤0.01% | 2882 |
|
|
2022
Q2 | $422K | Buy |
85,919
+13,710
| +19% | +$67.3K | ﹤0.01% | 3126 |
|
|
2022
Q1 | $1.71M | Buy |
72,209
+1,724
| +2% | +$40.8K | ﹤0.01% | 2702 |
|
|
2021
Q4 | $1.25M | Buy |
70,485
+3,137
| +5% | +$55.5K | ﹤0.01% | 2828 |
|
|
2021
Q3 | $1.9M | Buy |
67,348
+13,064
| +24% | +$369K | ﹤0.01% | 2708 |
|
|
2021
Q2 | $569K | Buy |
54,284
+10,654
| +24% | +$112K | ﹤0.01% | 3124 |
|
|
2021
Q1 | $514K | Buy |
43,630
+6,616
| +18% | +$77.9K | ﹤0.01% | 3068 |
|
|
2020
Q4 | $434K | Buy |
37,014
+4,306
| +13% | +$50.5K | ﹤0.01% | 3037 |
|
|
2020
Q3 | $260K | Buy |
32,708
+2,910
| +10% | +$23.1K | ﹤0.01% | 3087 |
|
|
2020
Q2 | $546K | Buy |
29,798
+3,029
| +11% | +$55.5K | ﹤0.01% | 2793 |
|
|
2020
Q1 | $320K | Buy |
+26,769
| New | +$320K | ﹤0.01% | 2867 |
|